Golden Cross Stocks
XNCR recently triggered a golden cross, indicating that its short-term trend has turned bullish relative to its long-term trend.
XENCOR INC (XNCR) Stock Price & Overview
NASDAQ:XNCR • US98401F1057
Current stock price
12.8 USD
-0.26 (-1.99%)
At close:
12.8 USD
0 (0%)
After Hours:
The current stock price of XNCR is 12.8 USD. Today XNCR is down by -1.99%. In the past month the price increased by 5.52%. In the past year, price increased by 21.79%.
XNCR Key Statistics
52-Week Range6.92 - 18.69
Current XNCR stock price positioned within its 52-week range.
1-Month Range10.96 - 13.4
Current XNCR stock price positioned within its 1-month range.
- Market Cap
- 938.752M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.24
- Dividend Yield
- N/A
XNCR Stock Performance
Today
-1.99%
1 Week
+6.05%
1 Month
+5.52%
3 Months
+0.16%
Longer-term
6 Months -3.10%
1 Year +21.79%
2 Years -38.87%
3 Years -51.59%
5 Years -69.92%
10 Years +4.49%
XNCR Stock Chart
XNCR Stock Screens
XNCR currently appears in the following ChartMill screener lists.
XNCR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to XNCR. When comparing the yearly performance of all stocks, XNCR turns out to be only a medium performer in the overall market: it outperformed 57.91% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
XNCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XNCR. XNCR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
XNCR Earnings
On February 25, 2026 XNCR reported an EPS of -0.09 and a revenue of 28.24M. The company beat EPS expectations (85.37% surprise) and missed revenue expectations (-12.63% surprise).
Next Earnings DateMay 13, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.09
Revenue Reported28.237M
EPS Surprise 85.37%
Revenue Surprise -12.63%
XNCR Forecast & Estimates
20 analysts have analysed XNCR and the average price target is 28.93 USD. This implies a price increase of 125.99% is expected in the next year compared to the current price of 12.8.
For the next year, analysts expect an EPS growth of -139.6% and a revenue growth -7.68% for XNCR
Analysts
Analysts83
Price Target28.93 (126.02%)
EPS Next Y-139.6%
Revenue Next Year-7.68%
XNCR Groups
Sector & Classification
XNCR Financial Highlights
Over the last trailing twelve months XNCR reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS increased by 64.67% compared to the year before.
Income Statements
Revenue(TTM)125.58M
Net Income(TTM)-91.92M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.5% | ||
| ROE | -14.46% | ||
| Debt/Equity | 0.12 |
Chartmill High Growth Momentum
EPS Q2Q%85.48%
Sales Q2Q%-46.51%
EPS 1Y (TTM)64.67%
Revenue 1Y (TTM)13.65%
XNCR Ownership
Ownership
Inst Owners119.48%
Shares73.34M
Float72.27M
Ins Owners1.25%
Short Float %15.63%
Short Ratio14.17
XNCR Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.74 | 368.574B | ||
| AMGN | AMGEN INC | 15.33 | 191.752B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 170.842B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 112.224B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.99 | 79.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.55 | 41.318B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.537B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.454B | ||
| BIIB | BIOGEN INC | 11.37 | 26.028B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.789B | ||
| MRNA | MODERNA INC | N/A | 21.305B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.501B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XNCR
Company Profile
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 260 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Company Info
IPO: 2013-12-03
XENCOR INC
465 N. Halstead St., Suite 200
Pasadena CALIFORNIA 91016 US
CEO: Bassil I. Dahiyat
Employees: 260
Phone: 16263055900
XENCOR INC / XNCR FAQ
Can you describe the business of XENCOR INC?
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 260 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Can you provide the latest stock price for XENCOR INC?
The current stock price of XNCR is 12.8 USD. The price decreased by -1.99% in the last trading session.
Does XNCR stock pay dividends?
XNCR does not pay a dividend.
What is the ChartMill rating of XENCOR INC stock?
XNCR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is XENCOR INC (XNCR) stock traded?
XNCR stock is listed on the Nasdaq exchange.
What is XENCOR INC worth?
XENCOR INC (XNCR) has a market capitalization of 938.75M USD. This makes XNCR a Small Cap stock.
What is the ownership structure of XENCOR INC (XNCR)?
You can find the ownership structure of XENCOR INC (XNCR) on the Ownership tab.